menu
    • menu

    Company profile for Alys Pharmaceuticals

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Established in February 2024, Alys Pharmaceuticals emerges as a pioneering force in immuno-dermatology, a venture co-founded by Medixci in collaboration with renowned dermatology and scientific experts worldwide. Formed through the integration of six asset-centric Medixci companies, Alys proudly presents a formidable pipeline of inventive programs and platforms designed to address various dermatological conditions. Guided by a...
    Established in February 2024, Alys Pharmaceuticals emerges as a pioneering force in immuno-dermatology, a venture co-founded by Medixci in collaboration with renowned dermatology and scientific experts worldwide. Formed through the integration of six asset-centric Medixci companies, Alys proudly presents a formidable pipeline of inventive programs and platforms designed to address various dermatological conditions. Guided by a vision to revolutionize the treatment landscape for prevalent dermatological indications characterized by substantial unmet medical needs, Alys aims to reshape the paradigm of dermatological treatments.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Alys PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Boston Massachusetts 02210
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://alyspharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/alys-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alys Pharma Doses First Subject in Ph 1/1b Chronic Urticaria
    Alys Pharma Doses First Subject in Ph 1/1b Chronic Urticaria

    30 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alys-pharmaceuticals-doses-first-subject-in-phase-11b-trial-of-aly-301-a-first-in-class-mast-cell-selective-c-kit-inhibitor-for-chronic-urticaria-302598702.html

    PR NEWSWIRE
    30 Oct 2025
    Share Share
    Alys Pharmaceuticals Submits CTA for ALY-301 in Cold Urticaria
    Alys Pharmaceuticals Submits CTA for ALY-301 in Cold Urticaria

    10 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alys-pharmaceuticals-announces-cta-submission-for-aly-301-the-first-mast-cell-selective-c-kit-inhibitor-for-treatment-of-cold-urticaria-302476572.html

    PR NEWSWIRE
    10 Jun 2025
    Share Share
    Alys Pharma Starts Phase IIa Trial of ALY-101 for Alopecia Areata
    Alys Pharma Starts Phase IIa Trial of ALY-101 for Alopecia Areata

    27 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alys-pharmaceuticals-announces-dosing-of-first-patient-in-phase-iia-trial-of-aly-101-for-alopecia-areata-302412452.html

    PR NEWSWIRE
    27 Mar 2025
    Share Share
    Alys Pharma Receives IND Clearance for Phase 2a Dermatology Trial
    Alys Pharma Receives IND Clearance for Phase 2a Dermatology Trial

    04 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alys-pharmaceuticals-receives-ind-clearance-for-phase-2a-trial-of-first-genetic-medicine-program-in-dermatology-302366489.html

    PR NEWSWIRE
    04 Feb 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search